menu
    • menu
    [{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"Melatonin receptor type 1A","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Not Applicable"},{"orgOrder":0,"company":"Kinderfarms","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Kinderfarms","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Kinderfarms \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kinderfarms \/ Not Applicable"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"O-Bank Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ O-Bank Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ O-Bank Co., Ltd."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Melatonin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Neurim Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurim Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Melatonin

    Menu

    Melatonin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neurim Pharmaceuticals

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Neurim Pharmaceuticals

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neurim Receives Positive CHMP Opinion for Slenyto® in Children with Neurogenic Insomnia

                            Details : Slenyto (melatonin) is an approved melatonin receptor agonist, which is currently being evaluated for the treatment of insomnia in children with neurogenetic disorders.

                            Brand Name : Slenyto

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 30, 2024

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IGC Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IGC Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Bradbury Asset Management

                            Deal Size : $3.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

                            Details : The net proceeds will be used for advancing company's investigational medicines including IGC-AD1, a natural THC-based oral formulation, for agitation in dementia from Alzheimer’s disease.

                            Brand Name : IGC-AD1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 26, 2024

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Bradbury Asset Management

                            Deal Size : $3.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IGC Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IGC Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial

                            Details : IGC-AD1, a combination medicine with a CB1 receptor partial agonist with anti-neuroinflammatory properties. It is under phase 2 clinical development for the treatment of dementia due to Alzheimer’s.

                            Brand Name : IGC-AD1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 17, 2024

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            IGC Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IGC Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : O-Bank Co., Ltd.

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research

                            Details : The funding will support IGC’s working capital needs primarily related to its Alzheimer’s research, with IGC-AD1, a low-dose tetrahydrocannabinol based formulation, currently in Phase 2 of clinical trials as a potential treatment for agitation in dem...

                            Brand Name : IGC-AD1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 07, 2023

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : O-Bank Co., Ltd.

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IGC Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IGC Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Bradbury Asset Management

                            Deal Size : $3.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            IGC Pharma Announces a $3 Million Private Placement of its Common Stock

                            Details : The funds will support the advancement of the Company’s Phase-2 clinical trial of IGC-AD1 (tetrahydrocannabinol), the Company’s promising investigational drug candidate designed to address agitation in dementia caused by Alzheimer's disease.

                            Brand Name : IGC-AD1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 06, 2023

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Bradbury Asset Management

                            Deal Size : $3.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            IGC Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IGC Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC

                            Details : This is a phase I Multiple Ascending Dose (MAD) study to evaluate safety and tolerability of IGC-AD1 (tetrahydrocannabinol) in subjects with AD. Twelve subjects will be enrolled. Three different ascending doses of the study product will be given: low, me...

                            Brand Name : IGC-AD1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2022

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cleveland Clinic

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cleveland Clinic Research Shows that Melatonin is a Promising Candidate for Prevention and Treatment of COVID-...

                            Details : Results from a new Cleveland Clinic-led study suggest that melatonin, a hormone that regulates the sleep-wake cycle and is commonly used as an over-the-counter sleep aid, may be a viable treatment option for COVID-19.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 13, 2020

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kinderfarms

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kinderfarms

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin,Apigenin

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kinderfarms Announces the Launch of Kinderlyte® Sleep and Immunity

                            Details : Kinderlyte's Herbal Sleep Supplement is a doctor-formulated, drug-free sleep aid that uses a proprietary blend of melatonin and calming botanicals such as chamomile, passionflower, and lemon balm to support sleep.

                            Brand Name : Kinderlyte Sleep

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 30, 2020

                            Lead Product(s) : Melatonin,Apigenin

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cleveland Clinic

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cleveland Clinic

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin,Mercaptopurine,Sirolimus

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Melatonin? Stem Cells? Researchers Step Up With Unconventional Approaches To COVID-19

                            Details : Cleveland Clinic compared COVID-19 with the coronavirus that caused the SARS outbreak of 2003 using a technique called “network proximity analysis” to identify combinations of existing drugs.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 16, 2020

                            Lead Product(s) : Melatonin,Mercaptopurine,Sirolimus

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth